These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 33108509)

  • 21. [A novel approach to rapid induction of remission in primary membranous nephropathy].
    Dobronravov VA; Bystrova OB; Kochoyan ZS; Fomicheva EN
    Ter Arkh; 2021 Jun; 93(6):706-712. PubMed ID: 36286838
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of rituximab in patients with PLA2R-associated membranous nephropathy and malignancy.
    Guo Y; Ren M; Wang Y; Zhai Z; Yu L; Wang L; Tang L
    Int Immunopharmacol; 2024 Jan; 126():111327. PubMed ID: 38056198
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PLA2R-IgG4 antibody as a predictive biomarker of treatment effectiveness and prognostic evaluation in patients with idiopathic membranous nephropathy: a retrospective study.
    Huang Y; Zhou J; Zhou K; Huang B; Xue J; Zhang X; Liu B; Zhang Z; Zhou L; Cai T; Zhang Y; Hu Z; Wang L; Liu X
    PeerJ; 2022; 10():e14193. PubMed ID: 36248712
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antibodies to m-type phospholipase A2 receptor in children with idiopathic membranous nephropathy.
    Kumar V; Ramachandran R; Kumar A; Nada R; Suri D; Gupta A; Kohli HS; Gupta KL; Jha V
    Nephrology (Carlton); 2015 Aug; 20(8):572-5. PubMed ID: 26194981
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of rituximab in patients with idiopathic membranous nephropathy: a case series and literature review.
    Jeon SJ; Kim JH; Noh HW; Lee GY; Lim JH; Jung HY; Cho JH; Choi JY; Kim CD; Kim YL; Park SH
    Korean J Intern Med; 2022 Jul; 37(4):830-840. PubMed ID: 35421909
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rituximab for Severe Membranous Nephropathy: A 6-Month Trial with Extended Follow-Up.
    Dahan K; Debiec H; Plaisier E; Cachanado M; Rousseau A; Wakselman L; Michel PA; Mihout F; Dussol B; Matignon M; Mousson C; Simon T; Ronco P;
    J Am Soc Nephrol; 2017 Jan; 28(1):348-358. PubMed ID: 27352623
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intravenous pulse cyclophosphamide and steroids induce immunological and clinical remission in New-incident and relapsing primary membranous nephropathy.
    Kanigicherla DAK; Hamilton P; Czapla K; Brenchley PE
    Nephrology (Carlton); 2018 Jan; 23(1):60-68. PubMed ID: 27778424
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diagnostic performance of glomerular PLA2R and THSD7A antibodies in biopsy confirmed primary membranous nephropathy in South Africans.
    Lwezaula BF; Ameh OI; Ekrikpo UE; Botha FC; Okpechi-Samuel US; Wearne N; Ronco P; Bello AK; Okpechi IG
    BMC Nephrol; 2021 Jan; 22(1):15. PubMed ID: 33413188
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New insights into immune mechanisms underlying response to Rituximab in patients with membranous nephropathy: A prospective study and a review of the literature.
    Roccatello D; Sciascia S; Di Simone D; Solfietti L; Naretto C; Fenoglio R; Baldovino S; Menegatti E
    Autoimmun Rev; 2016 Jun; 15(6):529-38. PubMed ID: 26876383
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Long-term efficacy of low-dose rituximab treatment in patients with primary membranous nephropathy].
    Qi Y; Jia JY; Gu QH; Zheng ZF; Li LN; Li D; Jia ZH; Xue Y; Yan TK
    Zhonghua Yi Xue Za Zhi; 2022 Nov; 102(40):3201-3206. PubMed ID: 36319174
    [No Abstract]   [Full Text] [Related]  

  • 31. Retrospective analysis of
    Guo Y; Guo N; Wang J; Wang R; Tang L
    Ren Fail; 2021 Dec; 43(1):729-736. PubMed ID: 33904354
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of rituximab in patients with PLA2R associated membranous nephropathy and resolved HCV infection.
    Li X; Song D; Hao Y; Ren M; Guo Y; Zhao H; Wang Y; Tang L
    Sci Rep; 2024 Sep; 14(1):20981. PubMed ID: 39251782
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PLA2R antibody levels and clinical outcome in patients with membranous nephropathy and non-nephrotic range proteinuria under treatment with inhibitors of the renin-angiotensin system.
    Hoxha E; Harendza S; Pinnschmidt H; Panzer U; Stahl RA
    PLoS One; 2014; 9(10):e110681. PubMed ID: 25313791
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recurrent Membranous Nephropathy After Kidney Transplantation Associated With Phospholipase A2 Receptor and Successfully Treated With Rituximab: A Case Report.
    Ishiwatari A; Wakai S; Shirakawa H; Honda K
    Transplant Proc; 2018 Oct; 50(8):2565-2568. PubMed ID: 30316399
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of rituximab for primary membranous nephropathy with different clinical presentations: a retrospective study.
    Zhang S; Huang J; Dong J; Li Z; Sun M; Sun Y; Chen B
    Front Immunol; 2023; 14():1156470. PubMed ID: 37187749
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment resistant M-type phospholipase A2 receptor associated membranous nephropathy responds to obinutuzumab: a report of two cases.
    Hudson R; Rawlings C; Mon SY; Jefferis J; John GT
    BMC Nephrol; 2022 Apr; 23(1):134. PubMed ID: 35392837
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Primary membranous glomerulonephritis with negative serum PLA2R in haemophilia A successfully managed with rituximab - case report and review of the literature.
    Meyer N; Cooper W; Kirwan P; Garsia R; Dunkley S; Gracey DM
    BMC Nephrol; 2021 Jul; 22(1):268. PubMed ID: 34294065
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Membranous nephropathy with light chain restricted deposits.
    Ramachandran R; Inamdar N; Bharati J; Yadav AK; Kumar A; Prakash G; Nada R; Rathi M; Kohli HS; Gupta KL; Jha V
    Nephrology (Carlton); 2018 Aug; 23(8):791-796. PubMed ID: 29633425
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anti-Phospholipase A2 Receptor (Anti-PLA2R) Antibody in Diagnosis and Treatment of Idiopathic Membranous Nephropathy: A Single-Center Observational Study in China.
    Guo N; Cao Y; Dai H; Yuan L; Shi L; Zhang Y
    Med Sci Monit; 2019 Dec; 25():9364-9368. PubMed ID: 31813930
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association Between High NK-Cell Count and Remission of Primary Membranous Nephropathy: A Retrospective Chart Review and Pilot Study.
    Chen W; Cai J; Raffetseder U; Zhu B; Chen J; Song N; Li Y; Lu Y; Fang Y; Ding X; Wang J
    Clin Ther; 2023 Apr; 45(4):364-374. PubMed ID: 36997447
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.